Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 6/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574549 | 1.00 | LPL (0.39) | LPLLIPGTNFKMT2ALIPE | |
| SCHEMBL4315605 | 0.91 | KMT2A (0.35) | LPLLIPGTNFKMT2ALIPE | |
| SCHEMBL2026497 | 0.86 | LPL (0.38) | LPLLIPGTNFKMT2ALIPE | |
| SCHEMBL31648336 | 0.86 | JAK2 (0.38) | LPLLIPGTNFLIPENR1I2 | |
| SCHEMBL26197525 | 0.83 | LPL (0.33) | LPLLIPGTNFBACE1 | |
| SCHEMBL13727784 | 0.83 | LPL (0.41) | LPLLIPGTNFCXCR2 | |
| SCHEMBL29878543 | 0.83 | LPL (0.41) | LPLLIPGTNFCXCR2 | |
| SCHEMBL14358557 | 0.83 | LPL (0.41) | LPLLIPGTNFKMT2ALIPE | |
| SCHEMBL22131084 | 0.80 | LPL (0.44) | LPLLIPGLIPE | |
| SCHEMBL25367719 | 0.80 | MEN1 (0.36) | LPLLIPGKMT2ALIPESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2026-01-15 | — | — | US | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-01-07 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-114502535-B | Acid addition salts of rory modulators | 江苏恒瑞医药股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008135826-A2 | 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008135826-A2 | 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | LPL 4447/4885LIPG 4853/4885TNF 2662/4885 |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | LPL 2017/4885LIPG 1727/4885TNF 4669/4885 |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | POLB, POLA1, POLN | LPL 1951/4885LIPG 1995/4885TNF 4786/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | LPL 3982/4885LIPG 2426/4885TNF 4086/4885 |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | LPL 4301/4885LIPG 2925/4885TNF 4407/4885 |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | LPL 3931/4885LIPG 4769/4885TNF 959/4885 |
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | RORC, RORB, RORA | LPL 2423/4885LIPG 3577/4885TNF 2626/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | LPL 3923/4885LIPG 3144/4885TNF 4230/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | LPL 1462/4885LIPG 2091/4885TNF 3415/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | LPL 4181/4885LIPG 3541/4885TNF 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.